Dendreon to Host Conference Call on September 8, 2011 to Discuss Company Restructuring

SEATTLE--(BUSINESS WIRE)-- Dendreon Corporation (NASDAQ:DNDN) today announced that management will host a conference call on Thursday, September 8, 2011 at 4:30 p.m. ET to provide a structural and business update on the company.

Access to the discussion may be obtained as follows:
 
Time:  

4:30 p.m. ET / 1:30 p.m. PT

Date: September 8, 2011
Dial-In: (877) 548-9590
International Dial-In: (720) 545-0037
Conference ID: 97761940
Webcast:

www.dendreon.com (homepage and investor relations section)

 

A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-855-859-2056 (toll-free) or 404-537-3406 (international). The replay will be available from 7:30 p.m. ET on September 8 until 11:59 p.m. ET on September 15. In addition the webcast will be archived for on-demand listening for 30 days at www.dendreon.com.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGEĀ® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.



CONTACT:

Dendreon Corporation
V.P. Corporate Communications & Investor Relations
Katherine Stueland, 206-829-1522

KEYWORDS:   United States  North America  Washington

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology

MEDIA:

Logo
 Logo

Suggested Articles

Omega Therapeutics is working on treatments that adjust gene expression up or down without making permanent changes to the genome.

The IPO window is still wide open for biotech, and French Big Pharma-partnered Innate is looking to jump right on through.

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.